Teva Pharmaceutical Industries Ltd is a fully integrated global pharmaceutical company, focusing its business in 3 primary areas: generic, specialty, and OTC medicines. Approximately 51% of the company’s revenue is generated in the US.
Teva Pharmaceuticals is the leading generic drug company in the US. In 2012, Teva accounted for 16.2% of US generic prescriptions, with 1 of every 6* generic prescriptions being filled with a Teva product. The company’s strategy for its generic business is to continue to extract maximum value from Paragraph IV patent challenge opportunities; establish a leadership position in high-value generics by pursuing first-to-market opportunities and by developing complex generic products; and to enhance the value of its portfolio by concentrating on high-margin, low-competition markets.
*IMS Health NPA data as of 12/2012.
Teva’s Levalbuterol Inhalation Solution, USP, AN rated to Xopenex® (levalbuterol HCl) Inhalation Solution.
Teva recently introduced generic versions of Maxalt® (rizatriptan benzoate) Tablets.
Teva has 144 ANDAs pending FDA approval as of April 18, 2013, and introduced 23 generic products in 2012. The company markets the broadest product line in the industry, with nearly 400 generic products and 1300 dosage strengths and package sizes, covering all major therapeutic categories. Teva also produces approximately 300 APIs in many therapeutic areas.
Teva’s strategy also includes a disciplined and focused approach to enhancing its specialty-branded portfolio, concentrating on the therapeutic areas of CNS, respiratory, oncology, and women’s health. Teva’s specialty portfolio includes COPAXONE®, AZILECT®, NUVIGIL®, ProAir®, and TREANDA®. As part of this strategy, Teva is focusing on new therapeutic entities (“NTEs”), which are known molecules that are formulated, delivered, or used in a novel way to address specific patient needs.
1090 Horsham Road
P.O. Box 1090 North Wales, PA 19454-1090
For more information, visit tevausa.com